Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Other Liabilities Noncurrent

Other Liabilities Noncurrent at other companies

SharkNinja logo
SharkNinjaSN
$52.71M
Taboola.com Ltd. logo
Taboola.com Ltd.TBLA
$17.24M+36.6%
United Therapeutics logo
United TherapeuticsUTHR
$212M+2.3%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$2.7M+72.7%
SLD
Solid PowerSLDP
$1.09M-4.9%
CVS Health logo
CVS HealthCVS
$6.11B+27.8%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-28.6%
Enterprise value$1.22B-37.5%
P/S31×-5.9×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemJune 30, 2026December 31, 2025
Operating lease liabilities, non-current39,19346,647
Notes payable and financing lease liabilities, non-current4,7539,564
Deferred tax liabilities18,31323,255
Other liabilities, non-current2,7022,080
Total liabilities297,665343,265
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively55

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s other liabilities noncurrent?
Recursion Pharmaceuticals, Inc. (RXRX) reported other liabilities noncurrent of $2.7M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s other liabilities noncurrent changed year-over-year?
Recursion Pharmaceuticals, Inc.'s other liabilities noncurrent increased by 72.7% year-over-year, from $1.57M to $2.7M.
What does other liabilities noncurrent mean?
Other Liabilities Noncurrent as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.

Ask your AI about Recursion Pharmaceuticals, Inc.'s other liabilities noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude